FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921098081> ?p ?o ?g. }

• W2921098081 endingPage "2264" @default.
• W2921098081 startingPage "2264" @default.
• W2921098081 abstract "Abstract Background: Therapy studies yield important insights into clinical features and therapeutic options of CLL. However studies in Germany represent less then 20% of all CLL patients (pts); pts >75 years (yrs) are included in 3% only. Furthermore initial phases are not reflected in multicenter studies and data representing real life situation are scarce. Methods: Out of 1.443 patients consulting our center because of leucocytosis (>10 Gpt/l) between 2003/07/01 and 2018/06/30 we diagnosed CLL consecutively in 234 pts (16,2%): 143 male (m), 91 female (f). Median age at diagnosis is 71,4 yrs. Median leucocyte count is 18,0 Gpt/l. BINET - Stages are: A in 82%, B in 11% and C in 7% of pts. Diagnoses are strictly based on WHO definition: Pts with small lymphocytic lymphomas (sLL, n=11) are included but those with monoclonal lymphocytosis of unknown significance (MLUS) or monoclonal B - lymphocytoses with uncertainly flow cytometry (FC) results are excluded. Histopathology, FC and genetics have been performed by external hematological reference laboratories. All investigations followed the rules of best clinical and laboratory practice. Dates of death are given by the record sections of the involved communities (deadline 2018/06/30). To address different questions we defined 3 groups of pts: A: collective group, (n=234), i.e. all pts.diagnosed from 2003/07/01 to 2018/06/30. B: epidemiological group (n=129), i.e. pts from 3 communities (113.000 inhabitants - inc - in 2009/12/31) in close proximity referred to our center. C: genetic features group (n=99), i.e. pts diagnosed continuously between 2012/07/01 and 2018/06/30 with systematically performed genetics, (i.e. at least 80% of pts in this group. Genetics are: Cytogenetic (banding) n=88; FISH (del 6q21/6q, del 11q22.3, +12/+12q, del 13q14/ 13q34, del 17p13.1, 14q32) n=85. PCR (IgVH status - mutated vs. unmutated; TP53, NOTCH1, SF3B1 mutation) n=82. Results: Collective group (A): 7,5 years OS is 72% and 15 years OS is 33% respectively (KAPLAN-MEIER). Age of pts acts as a predominant factor for long term OS: 77% in pts < 60 yrs vs. 40% in pts ≥60 to <75 yrs vs. 16% in pts ≥75 yrs. 15 yrs OS of treated pts is 32% (n=78, median age at diagnosis: 73,3 yrs, m : f = 1,50); 15 yrs OS of untreated patients is 33% (n=146, median age at diagnosis: 71,0 yrs, m : f = 1,56). Mean time to 1st treatment was 16,0 month (0,1 to 132,6 months). Epidemiological group (B): Raw incidence is 7,56/105 inh. (m: 9,13, f: 6,06), age adjusted incidence is 10,3/105 inh (m: 12,5, f: 8,3), with highest rate of age between 75 to < 80 yrs. Standard incidence is calculated as 6,27/105 (BRD 1987), 4,78/105 (Europe) and 5,06/105 (USA 2000). Prevalence could be measured directly (2017-12-31): 79,1/105 inh. Genetic features group (C): IgVH mutation status is hypermutated in 48 pts. vs. unmutated in 39 pts. Results of FISH analyses (n = 85) are: del 6: 5,5%, del 11: 17,6%, +12: 3%, del 13q: 70,3%, del 17p: 8,8%; normal status: 13,2%. PCR revealed mutations of NOTCH1 in 7%, of SF3B1 in 10,5% and of TP53 in 8,6% of 82 pts, respectively. Combined del17p by FISH and molecular TP53 mutations at diagnosis are found in 3 of 81 pts (3,7%). Cytogenetic findings different to results of FISH and/or PCR were found in 36 of 82 pts (43,9%). Calculated 5 yrs freedom of therapy is 75% in IgVH hypermutated pts vs. 45% in unmutated pts (p = 0,0005; log rank test); calculated 5 yrs OS is 92% vs. 59% (p=0,023). Special situations in CLL: 13 of 234 pts (5,5%) have one parent or sibling with low grade NHL, mostly CLL. In contrast there is non spouse suffering of CLL / low grade NHL. Deficiency in Immunoglobuline G (Ig G < 4,0 g/l) was found in 17 of 199 pts at diagnose (8,5%), 29 pts (12,4%) were substituted with Ig G's in the Course of CLL. In 14 (6,0%) pts. we diagnosed a 2nd hematologic malignancy (3x cMPN, 1x CML, 3x MDS, 3x AML, 1x FL, 1x MCL, 1x MZL, 1x DLCBL-independent of CLL; monoclonal gammopathies are not considered). RICHTER syndrome was found in 1 case, but progression to plasmocytic/plasmoblastic disease was seen in 3 cases. Li FRAUMENI Syndrome was revealed in 1 male patient, he has been in stable disease for 13 yrs. Conclusion: CLL seems to be more frequent than yet considered. IgVH mutation status seems to be very important as a single prognostic factor concerning time of 1st therapy as well as OS. Clinical features of CLL are very different and impressing. Disclosures Böttcher: Genentech: Research Funding; Janssen: Honoraria; AbbVie: Honoraria, Research Funding; Celgene: Research Funding; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2921098081 created "2019-03-22" @default.
• W2921098081 creator A5020466742 @default.
• W2921098081 creator A5025663121 @default.
• W2921098081 creator A5031782622 @default.
• W2921098081 creator A5039267861 @default.
• W2921098081 creator A5055437254 @default.
• W2921098081 creator A5073538398 @default.
• W2921098081 creator A5081642625 @default.
• W2921098081 creator A5088699891 @default.
• W2921098081 creator A5004635132 @default.
• W2921098081 date "2018-11-29" @default.
• W2921098081 modified "2023-09-27" @default.
• W2921098081 title "Real Life Dates of Chronic Lymphocytic Leukemia (CLL) in Germany. Interim Analysis of 234 Consecutively New Diagnosed Patients in a German Epidemiological-Clinical Register" @default.
• W2921098081 doi "https://doi.org/10.1182/blood-2018-99-110618" @default.
• W2921098081 hasPublicationYear "2018" @default.
• W2921098081 type Work @default.
• W2921098081 sameAs 2921098081 @default.
• W2921098081 citedByCount "0" @default.
• W2921098081 crossrefType "journal-article" @default.
• W2921098081 hasAuthorship W2921098081A5004635132 @default.
• W2921098081 hasAuthorship W2921098081A5020466742 @default.
• W2921098081 hasAuthorship W2921098081A5025663121 @default.
• W2921098081 hasAuthorship W2921098081A5031782622 @default.
• W2921098081 hasAuthorship W2921098081A5039267861 @default.
• W2921098081 hasAuthorship W2921098081A5055437254 @default.
• W2921098081 hasAuthorship W2921098081A5073538398 @default.
• W2921098081 hasAuthorship W2921098081A5081642625 @default.
• W2921098081 hasAuthorship W2921098081A5088699891 @default.
• W2921098081 hasConcept C107130276 @default.
• W2921098081 hasConcept C126322002 @default.
• W2921098081 hasConcept C187212893 @default.
• W2921098081 hasConcept C2777938653 @default.
• W2921098081 hasConcept C2778461978 @default.
• W2921098081 hasConcept C2780126324 @default.
• W2921098081 hasConcept C535046627 @default.
• W2921098081 hasConcept C61943457 @default.
• W2921098081 hasConcept C71924100 @default.
• W2921098081 hasConceptScore W2921098081C107130276 @default.
• W2921098081 hasConceptScore W2921098081C126322002 @default.
• W2921098081 hasConceptScore W2921098081C187212893 @default.
• W2921098081 hasConceptScore W2921098081C2777938653 @default.
• W2921098081 hasConceptScore W2921098081C2778461978 @default.
• W2921098081 hasConceptScore W2921098081C2780126324 @default.
• W2921098081 hasConceptScore W2921098081C535046627 @default.
• W2921098081 hasConceptScore W2921098081C61943457 @default.
• W2921098081 hasConceptScore W2921098081C71924100 @default.
• W2921098081 hasIssue "Supplement 1" @default.
• W2921098081 hasLocation W29210980811 @default.
• W2921098081 hasOpenAccess W2921098081 @default.
• W2921098081 hasPrimaryLocation W29210980811 @default.
• W2921098081 hasRelatedWork W129333680 @default.
• W2921098081 hasRelatedWork W17488461 @default.
• W2921098081 hasRelatedWork W1899509814 @default.
• W2921098081 hasRelatedWork W1970108590 @default.
• W2921098081 hasRelatedWork W2038109132 @default.
• W2921098081 hasRelatedWork W2092652240 @default.
• W2921098081 hasRelatedWork W2252678874 @default.
• W2921098081 hasRelatedWork W252467778 @default.
• W2921098081 hasRelatedWork W2606727070 @default.
• W2921098081 hasRelatedWork W40583498 @default.
• W2921098081 hasVolume "132" @default.
• W2921098081 isParatext "false" @default.
• W2921098081 isRetracted "false" @default.
• W2921098081 magId "2921098081" @default.
• W2921098081 workType "article" @default.